NAD+

NAD+ is a coenzyme your cells already use to process energy. People discuss injections, IV drips and nasal sprays for fatigue, brain fog and a feeling of being recharged. Reports range from clearer thinking to no worthwhile change, and some people feel nauseated, anxious or exhausted instead.

A cellular helper, rather than a peptide or a stimulant. Nicotinamide adenine dinucleotide helps cells transfer electrons and supplies enzymes involved in repair. The appeal of adding more is a cellular recharge; that biological role does not establish that an injection restores energy or slows aging. Grant et al. (2019): human plasma and urine NAD+ metabolome during a six-hour infusion (Official context · Accessed 2026-09-30)

NAD+, NADH, NMN and NR are different forms or compounds. NADH is the reduced partner of NAD+. NMN and NR are precursors used to make NAD+, often discussed as daily oral alternatives. Direct NAD+ discussions include SubQ, IV, IM and nasal products. A labeled milligram is not interchangeable across those compounds or routes.

Source context — Grant et al. (2019): human plasma and urine NAD+ metabolome during a six-hour infusion: Eight NAD+ participants and three controls, healthy men, six-hour IV exposure and only two hours after infusion. Formal biochemical context, no terminal half-life or efficacy outcome; clinic/company funding and director/consultant conflicts disclosed. Does not transfer to SubQ, IM or nasal.

Less fatigue and more willingness to get things done. A retatrutide user described renewed focus and energy on the first day of SubQ use. A longer-term reply described motivation without a coffee-like rush. Neither measured an NAD+ deficiency. Dosage of NAD+ & Schedule Injection (Community discussion · Accessed 2026-09-30)

A clearer head, with inconsistent sleep and recovery claims. A SubQ user described sharper thinking and better sleep while also taking glutathione and vitamin C. Another participant in that thread reported no effect after repeated attempts. Longevity, travel recovery and burnout are reasons people seek NAD+, not outcomes established by those experiences. Nad+ — changed SubQ frequency and null response (Community discussion · Accessed 2026-09-30)

NAD+ is a coenzyme your cells already use to process energy. People discuss injections, IV drips and nasal sprays for fatigue, brain fog and a feeling of being recharged. Reports range from clearer thinking to no worthwhile change, and some people feel nauseated, anxious or exhausted instead.

An early IV diary described 2–3 days of benefit, then revised its conclusion. The same author later rejected a meaningful overall benefit. The existing 2–7-day fade narrative cannot establish that further use maintains an effect. NAD+ IV Therapy — complete four-week diary (Personal report · Accessed 2026-09-30)

Source context — Dosage of NAD+ & Schedule Injection: Unverified self-reports, GLP-1/retatrutide co-use. OP's twice-weekly schedule is a plan, not a completed course. OP later posts a referral link. A separate commenter circulating a schedule is not evidence of efficacy or measured half-life. Syringe and preparation advice excluded.

Source context — Nad+ — changed SubQ frequency and null response: Dose and frequency changed together; multiple supplements; no product verification or objective outcome. Null reporter gives no route or amount. Positive sleep attribution is to the combination.

Source context — NAD+ IV Therapy — complete four-week diary: One unblinded commercial diary, not several independent reports. Early enthusiasm and later rejection belong to the same person. Planned maintenance was not demonstrated. No product assay or objective efficacy measurement; cost is historical self-report.

SubQ: 50–150 mg per injection in the existing chart record. Separate chart patterns include 20–200 mg per injection, 1–3 times weekly, or daily 25–50 mg. One actual first-day report used 50 mg; twice-weekly use was still a plan. No standard is established. Dosage of NAD+ & Schedule Injection (Community discussion · Accessed 2026-09-30)

50 mg three times weekly versus 40 mg five days weekly. One user reported no noticeable change during the first month at 150 mg/week, then felt sharper on injection days after switching to 200 mg/week for two weeks. Amount, frequency and concurrent supplements all changed the interpretation; this is not proof that daily use works better. Nad+ — changed SubQ frequency and null response (Community discussion · Accessed 2026-09-30)

IV: 250–750 mg per visit in the existing wellness-menu record. The record includes 100–200 mg introductory sessions, 250/500/1,000 mg tiers and intensive 1,000–1,500 mg visits. A separate advertised 3,000 mg monthly total refers to several visits, not one infusion or a safety ceiling.

IM: 50–200 mg, up to three times weekly, in older chart discussion. This is a separate pharmacy-style range in the existing record. It is not an IV conversion or evidence that an IM injection has the same benefit as SubQ.

Nasal: product strength varies sharply. Existing notes describe 25–50 mg per spray, with 1–2 sprays per nostril once or twice daily. People in the reviewed discussions instead mention 10 mg per spray and a labeled 170 mg per two-spray serving. These differing product claims cannot establish absorbed dose or an injection equivalent. Has anyone tried NAD+ nasal spray? — follow-ups, label strengths and breaks (Community discussion · Accessed 2026-09-30)

Source context — Dosage of NAD+ & Schedule Injection: Unverified self-reports, GLP-1/retatrutide co-use. OP's twice-weekly schedule is a plan, not a completed course. OP later posts a referral link. A separate commenter circulating a schedule is not evidence of efficacy or measured half-life. Syringe and preparation advice excluded.

Source context — Nad+ — changed SubQ frequency and null response: Dose and frequency changed together; multiple supplements; no product verification or objective outcome. Null reporter gives no route or amount. Positive sleep attribution is to the combination.

Source context — Has anyone tried NAD+ nasal spray? — follow-ups, label strengths and breaks: Unverified product labels and self-reports; branded recommendations and promotional links appear in discussion. Spray counts do not verify absorbed amount; pause/restart is uncontrolled. ADHD forum context does not establish an ADHD indication. Date-specific follow-ups are different from publication date of the OP.

SubQ: first-day relief in one account; no change for a month in another. These are different experiences; the delayed account also involved glutathione and vitamin C. Neither supplies a predictable onset window. Dosage of NAD+ & Schedule Injection (Community discussion · Accessed 2026-09-30) · Nad+ — changed SubQ frequency and null response (Community discussion · Accessed 2026-09-30)

IV: during the session in one reply; 24–72 hours in older reports. One commenter described brain fog lifting within an hour while the drip continued. The existing record describes next-day or 24–72-hour recharge claims. These are subjective observations, not blood-level peaks. NAD+ IV Therapy — complete four-week diary (Personal report · Accessed 2026-09-30)

Nasal: about 10 minutes in one early report, subtle changes over weeks in another. The rapid report involved NMN and euphoria. A separate diary noticed more after 30 days but still rejected its value; no shared onset is established. Been using NAD+ nasal spray the last few days, interested in hearing your experiences (Personal report · Accessed 2026-09-30) · Has anyone tried NAD+ nasal spray? — follow-ups, label strengths and breaks (Community discussion · Accessed 2026-09-30)

An early IV diary described 2–3 days of benefit, then revised its conclusion. The same author later rejected a meaningful overall benefit. The existing 2–7-day fade narrative cannot establish that further use maintains an effect. NAD+ IV Therapy — complete four-week diary (Personal report · Accessed 2026-09-30)

SubQ/nasal single-dose duration is unclear. Injection-day clarity and slightly more brain fog after a nasal off-week are different observations, not measurements of single-dose duration. Nad+ — changed SubQ frequency and null response (Community discussion · Accessed 2026-09-30) · Has anyone tried NAD+ nasal spray? — follow-ups, label strengths and breaks (Community discussion · Accessed 2026-09-30)

No usable route-specific numerical estimate in the inspected community accounts. Half-life means a measured amount falling by half. Reports of feeling better for days, injections spaced several days apart and hours spent on a drip do not measure it. The existing discussion likewise distinguishes infusion rate from elimination half-life; there is no dependable SubQ, IM or nasal number to extract here.

Source context — Dosage of NAD+ & Schedule Injection: Unverified self-reports, GLP-1/retatrutide co-use. OP's twice-weekly schedule is a plan, not a completed course. OP later posts a referral link. A separate commenter circulating a schedule is not evidence of efficacy or measured half-life. Syringe and preparation advice excluded.

Source context — Nad+ — changed SubQ frequency and null response: Dose and frequency changed together; multiple supplements; no product verification or objective outcome. Null reporter gives no route or amount. Positive sleep attribution is to the combination.

Source context — NAD+ IV Therapy — complete four-week diary: One unblinded commercial diary, not several independent reports. Early enthusiasm and later rejection belong to the same person. Planned maintenance was not demonstrated. No product assay or objective efficacy measurement; cost is historical self-report.

Source context — Been using NAD+ nasal spray the last few days, interested in hearing your experiences: Very early experience, ongoing NMN, named commercial spray with no assay. OP explicitly acknowledges a possible honeymoon period; no verified long-term result. Not evidence of psychiatric treatment or measured nasal absorption.

Source context — Has anyone tried NAD+ nasal spray? — follow-ups, label strengths and breaks: Unverified product labels and self-reports; branded recommendations and promotional links appear in discussion. Spray counts do not verify absorbed amount; pause/restart is uncontrolled. ADHD forum context does not establish an ADHD indication. Date-specific follow-ups are different from publication date of the OP.

SubQ schedules range from weekly use to multi-week courses. Existing charts include 50 mg weekly for four weeks followed by 100 mg weekly, or 2–3 injections weekly for 1–2 months before less frequent maintenance. Intensive commercial loading claims of 100–200 mg daily for 7–14 days are separate from those lower-frequency patterns.

A circulated SubQ course lasts ten weeks, repeated 2–3 times yearly. One commenter describes 25–100 mg per injection, reaching 100 mg 2–3 times weekly. This circulated schedule establishes neither an optimal cycle nor a required break. Dosage of NAD+ & Schedule Injection (Community discussion · Accessed 2026-09-30)

IV diary: 500 mg over two hours, twice weekly for four weeks. After eight visits totaling 4,000 mg, the author rejected its value. Monthly or quarterly maintenance remained a plan. NAD+ IV Therapy — complete four-week diary (Personal report · Accessed 2026-09-30)

Other clinic loads and maintenance schedules remain distinct. Existing clinic templates include 4–10 visits over 1–3 weeks, five in ten days, four consecutive days, or four over 2–3 weeks. Other loads use weekly 500–750 mg for 4–6 weeks; 1,500 mg across 7–10 days as 250/500/500/250 mg; or 250–500 mg twice weekly for four weeks, then weekly for 4–8 weeks. Maintenance varies from biweekly to every 4–8 weeks; sustained energy is not established.

Nasal breaks are preferences, not a settled requirement. One user prefers two months on/one off; another paused after two weeks. Existing notes describe cost/discomfort-driven breaks and separate open-ended daily precursor use. Has anyone tried NAD+ nasal spray? — follow-ups, label strengths and breaks (Community discussion · Accessed 2026-09-30)

Source context — Dosage of NAD+ & Schedule Injection: Unverified self-reports, GLP-1/retatrutide co-use. OP's twice-weekly schedule is a plan, not a completed course. OP later posts a referral link. A separate commenter circulating a schedule is not evidence of efficacy or measured half-life. Syringe and preparation advice excluded.

Source context — NAD+ IV Therapy — complete four-week diary: One unblinded commercial diary, not several independent reports. Early enthusiasm and later rejection belong to the same person. Planned maintenance was not demonstrated. No product assay or objective efficacy measurement; cost is historical self-report.

Source context — Has anyone tried NAD+ nasal spray? — follow-ups, label strengths and breaks: Unverified product labels and self-reports; branded recommendations and promotional links appear in discussion. Spray counts do not verify absorbed amount; pause/restart is uncontrolled. ADHD forum context does not establish an ADHD indication. Date-specific follow-ups are different from publication date of the OP.

NAD+ IV + Myers / B-complex / multivitamin drip: Same-visit vitamin bags are extremely common; confounds single-agent credit for energy. [community]

NAD+ + glutathione (IV push or separate bag): Popular “detox / redox” clinic pair; often same-day or adjacent visits. [community]

Stacks and lifestyle changes complicate credit. Existing discussion includes glutathione, B vitamins, NR/NMN, TMG, CoQ10/PQQ, urolithin A, Ca-AKG, resveratrol, apigenin, methylene blue, MOTS-c and SS-31. These pairings do not establish synergy. Rest, sleep, exercise and alcohol reduction can also change energy; an unpleasant response is not proof of detox or a need for another supplement. Terrible NAD Side Effects (Community discussion · Accessed 2026-09-30) · NAD IV — worsening symptoms after a first infusion (Personal report · Accessed 2026-09-30)

Source context — Terrible NAD Side Effects: Self-reported 50 mg SubQ with stated twice-weekly regimen. No assay or clinical cause established. Poor intake is disclosed, not proved causal. Other commenters' contamination and methyl-donor explanations remain speculation.

Source context — NAD IV — worsening symptoms after a first infusion: Amount not stated; initial post says infusion was around four hours earlier, not a precise symptom-start measurement. Concurrent glutathione/biotin/lysine and other protocols confound attribution. No resolved clinical assessment or symptom-duration follow-up inspected.

Local irritation and a wired-tired comedown appear in the existing record. Injection-site sting, redness or bruising, and nasal irritation, drip taste or congestion are described separately from later fatigue or headache. Product/formulation differences matter; these reports do not identify a safe concentration or establish that discomfort means a product is working.

Immediate flushing and anxiety can accompany prolonged nausea. A 50 mg SubQ reporter described flushing and anxiety settling within 15 minutes but severe nausea lasting almost two hours. Poor food intake was mentioned; replies blaming food, injection location, methylation or contamination do not establish the cause. Terrible NAD Side Effects (Community discussion · Accessed 2026-09-30)

A comfortable infusion does not rule out a later bad reaction. Writing about four hours after a first IV, one person described progressively worsening headache, chest tightness and exhaustion, with additional glutathione, biotin, lysine and other protocols involved. The post gives no precise symptom-start time. The existing notes flag chest pain, fainting and persistent breathing difficulty for medical assessment; forum reassurance about slowing a drip is insufficient. NAD IV — worsening symptoms after a first infusion (Personal report · Accessed 2026-09-30)

Injectable product quality is a real concern. The FDA reports severe chills, shaking, vomiting and fatigue after NAD+ injections, sometimes requiring treatment, consistent with excessive endotoxins. It warns against using food-grade ingredients for sterile drugs. This does not identify what caused any particular forum reaction. FDA reminds compounders to use ingredients suitable for sterile compounding (Official context · Accessed 2026-09-30)

Source context — Terrible NAD Side Effects: Self-reported 50 mg SubQ with stated twice-weekly regimen. No assay or clinical cause established. Poor intake is disclosed, not proved causal. Other commenters' contamination and methyl-donor explanations remain speculation.

Source context — NAD IV — worsening symptoms after a first infusion: Amount not stated; initial post says infusion was around four hours earlier, not a precise symptom-start measurement. Concurrent glutathione/biotin/lysine and other protocols confound attribution. No resolved clinical assessment or symptom-duration follow-up inspected.

Source context — FDA reminds compounders to use ingredients suitable for sterile compounding: Regulatory adverse-report warning, not frequency estimates, not proof every NAD+ product is contaminated and not a diagnosis for any Reddit reporter.